vs

Side-by-side financial comparison of HARTE HANKS INC (HHS) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $39.9M, roughly 1.9× HARTE HANKS INC). On growth, HARTE HANKS INC posted the faster year-over-year revenue change (-15.4% vs -36.9%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-6.6M). Over the past eight quarters, HARTE HANKS INC's revenue compounded faster (-6.4% CAGR vs -34.4%).

Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

HHS vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.9× larger
MED
$75.1M
$39.9M
HHS
Growing faster (revenue YoY)
HHS
HHS
+21.5% gap
HHS
-15.4%
-36.9%
MED
More free cash flow
HHS
HHS
$5.9M more FCF
HHS
$-686.0K
$-6.6M
MED
Faster 2-yr revenue CAGR
HHS
HHS
Annualised
HHS
-6.4%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HHS
HHS
MED
MED
Revenue
$39.9M
$75.1M
Net Profit
$2.2M
Gross Margin
69.4%
Operating Margin
-0.3%
-10.4%
Net Margin
5.5%
Revenue YoY
-15.4%
-36.9%
Net Profit YoY
EPS (diluted)
$0.30
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HHS
HHS
MED
MED
Q4 25
$39.9M
$75.1M
Q3 25
$39.5M
$89.4M
Q2 25
$38.6M
$105.6M
Q1 25
$41.6M
$115.7M
Q4 24
$47.1M
$119.0M
Q3 24
$47.6M
$140.2M
Q2 24
$45.0M
$168.6M
Q1 24
$45.4M
$174.7M
Net Profit
HHS
HHS
MED
MED
Q4 25
$2.2M
Q3 25
$-2.3M
$-2.3M
Q2 25
$-335.0K
$2.5M
Q1 25
$-392.0K
$-772.0K
Q4 24
Q3 24
$142.0K
$1.1M
Q2 24
$-27.8M
$-8.2M
Q1 24
$-171.0K
$8.3M
Gross Margin
HHS
HHS
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
HHS
HHS
MED
MED
Q4 25
-0.3%
-10.4%
Q3 25
1.3%
-4.6%
Q2 25
0.1%
-1.0%
Q1 25
-0.1%
-1.1%
Q4 24
-3.3%
0.6%
Q3 24
4.0%
1.5%
Q2 24
3.0%
-4.7%
Q1 24
0.8%
4.5%
Net Margin
HHS
HHS
MED
MED
Q4 25
5.5%
Q3 25
-5.8%
-2.5%
Q2 25
-0.9%
2.3%
Q1 25
-0.9%
-0.7%
Q4 24
Q3 24
0.3%
0.8%
Q2 24
-61.8%
-4.8%
Q1 24
-0.4%
4.8%
EPS (diluted)
HHS
HHS
MED
MED
Q4 25
$0.30
$-1.64
Q3 25
$-0.31
$-0.21
Q2 25
$-0.05
$0.22
Q1 25
$-0.05
$-0.07
Q4 24
$-0.31
$0.08
Q3 24
$0.02
$0.10
Q2 24
$-3.84
$-0.75
Q1 24
$-0.02
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HHS
HHS
MED
MED
Cash + ST InvestmentsLiquidity on hand
$5.6M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$20.5M
$198.9M
Total Assets
$91.8M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HHS
HHS
MED
MED
Q4 25
$5.6M
$167.3M
Q3 25
$6.5M
$173.5M
Q2 25
$4.8M
$162.7M
Q1 25
$9.0M
$164.6M
Q4 24
$9.8M
$162.3M
Q3 24
$5.9M
$170.0M
Q2 24
$11.0M
$163.5M
Q1 24
$11.5M
$156.4M
Stockholders' Equity
HHS
HHS
MED
MED
Q4 25
$20.5M
$198.9M
Q3 25
$19.9M
$214.7M
Q2 25
$22.2M
$216.0M
Q1 25
$21.4M
$211.0M
Q4 24
$21.7M
$210.1M
Q3 24
$21.0M
$207.3M
Q2 24
$20.6M
$205.3M
Q1 24
$20.0M
$211.0M
Total Assets
HHS
HHS
MED
MED
Q4 25
$91.8M
$248.0M
Q3 25
$92.7M
$268.2M
Q2 25
$95.0M
$269.3M
Q1 25
$100.6M
$280.0M
Q4 24
$101.8M
$284.2M
Q3 24
$108.1M
$291.2M
Q2 24
$109.7M
$293.5M
Q1 24
$113.4M
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HHS
HHS
MED
MED
Operating Cash FlowLast quarter
$737.0K
$-5.3M
Free Cash FlowOCF − Capex
$-686.0K
$-6.6M
FCF MarginFCF / Revenue
-1.7%
-8.8%
Capex IntensityCapex / Revenue
3.6%
1.8%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-4.5M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HHS
HHS
MED
MED
Q4 25
$737.0K
$-5.3M
Q3 25
$3.2M
$12.1M
Q2 25
$-4.8M
$-3.4M
Q1 25
$-818.0K
$3.4M
Q4 24
$4.0M
$-4.9M
Q3 24
$-2.9M
$9.1M
Q2 24
$1.6M
$13.1M
Q1 24
$-5.7M
$7.3M
Free Cash Flow
HHS
HHS
MED
MED
Q4 25
$-686.0K
$-6.6M
Q3 25
$2.2M
$10.8M
Q2 25
$-5.1M
$-4.8M
Q1 25
$-923.0K
$1.9M
Q4 24
$3.4M
$-7.2M
Q3 24
$-4.9M
$7.7M
Q2 24
$926.0K
$11.1M
Q1 24
$-6.2M
$5.4M
FCF Margin
HHS
HHS
MED
MED
Q4 25
-1.7%
-8.8%
Q3 25
5.5%
12.0%
Q2 25
-13.1%
-4.5%
Q1 25
-2.2%
1.6%
Q4 24
7.3%
-6.1%
Q3 24
-10.2%
5.5%
Q2 24
2.1%
6.6%
Q1 24
-13.7%
3.1%
Capex Intensity
HHS
HHS
MED
MED
Q4 25
3.6%
1.8%
Q3 25
2.5%
1.5%
Q2 25
0.6%
1.3%
Q1 25
0.3%
1.3%
Q4 24
1.3%
1.9%
Q3 24
4.0%
1.0%
Q2 24
1.5%
1.1%
Q1 24
1.2%
1.1%
Cash Conversion
HHS
HHS
MED
MED
Q4 25
0.33×
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
-20.76×
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HHS
HHS

Fulfillment And Logistics Services$17.3M43%
Customer Care$13.7M34%
Other$8.9M22%

MED
MED

Segment breakdown not available.

Related Comparisons